Cytek Biosciences, Inc. (CTKB)
Automate Your Wheel Strategy on CTKB
With Tiblio's Option Bot, you can configure your own wheel strategy including CTKB - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CTKB
- Rev/Share 1.5444
- Book/Share 2.9744
- PB 1.3751
- Debt/Equity 0.0374
- CurrentRatio 5.2249
- ROIC -0.0541
- MktCap 520345252.0
- FreeCF/Share 0.0872
- PFCF 47.0305
- PE -81.1061
- Debt/Assets 0.0286
- DivYield 0
- ROE -0.0166
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | CTKB | TD Cowen | Buy | Hold | -- | $4 | May 9, 2025 |
| Downgrade | CTKB | Goldman | Buy | Sell | $7 | $4.5 | Jan. 31, 2025 |
News
Cellares Selects Five Best-in-Class Technology Providers, Tecan, Advanced Instruments, Cytek Biosciences, Slingshot Biosciences and AltemisLab, to Expand Cell Q's Capabilities in Meeting Demands for Commercial Scale Cell Therapy Quality Control
Published: September 17, 2025 by: Business Wire
Sentiment: Neutral
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), announces multiple strategic technology partnerships to advance the Cell Q™, the first fully automated quality control testing platform purpose-built to match the commercial-scale throughput for cell therapy manufacturing. Cellares is unveiling these partnerships ahead of the 10th Annual CAR-TCR Summit, where it will, for the first time, present drug product release da.
Read More
Cytek Biosciences, Inc. (CTKB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:00 AM EDT Company Participants Wenbin Jiang - President, CEO & Chairman of the Board William McCombe - Chief Financial Officer Conference Call Participants Yih-Ming Tu - Morgan Stanley, Research Division Presentation Yih-Ming Tu Research Associate Good morning, everyone. Thank you for joining us on Day 3 of our Global Healthcare Conference.
Read More
Cytek Biosciences, Inc. (CTKB) Q1 2025 Earnings Call Transcript
Published: May 11, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Chad Wiatrowski - TD Cowen Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I would like to welcome everyone to the Cytek Biosciences First Quarter 2025 Earnings Conference Call.
Read More
Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript
Published: February 28, 2025 by: Seeking Alpha
Sentiment: Neutral
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Participants David Westenberg - Piper Sandler Matthew Sykes - Goldman Sachs Chad Wiatrowski - TD Cowen Harrison Parsons - Stephens Inc. Operator Thank you for standing by, and good day, everyone. My name is RG, and I will be your conference operator today.
Read More
About Cytek Biosciences, Inc. (CTKB)
- IPO Date 2021-07-23
- Website https://cytekbio.com
- Industry Medical - Devices
- CEO Wenbin Jiang
- Employees 663